Company Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.
Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction.
It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association.
The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012.
Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Country | CH |
| IPO Date | Feb 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Timothy Mark Dyer |
Contact Details
Address: Chemin des Mines, 9 Geneva, CH | |
| Website | https://www.addextherapeutics.com |
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J107 |
| ISIN Number | US00654J2069 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director |
| Lénaic Teyssédou | Head of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 6-K | Filing |
| Sep 30, 2024 | 6-K | Filing |
| Sep 19, 2024 | 6-K | Filing |
| Aug 27, 2024 | 6-K | Filing |
| Aug 14, 2024 | SC 13D/A | [Amend] Filing |
| Aug 05, 2024 | SC 13D/A | [Amend] Filing |
| Jul 22, 2024 | 6-K | Filing |
| Jul 15, 2024 | 6-K | Filing |
| Jul 01, 2024 | 6-K | Filing |
| Jun 06, 2024 | 6-K | Filing |